Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in District of Columbia: - Site 104 — Washington D.C., District of Columbia
Phase 3 Recruiting Industry
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in District of Columbia: - George Washington University Cancer Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in District of Columbia: - Local Institution - 2106 — Washington D.C., District of Columbia
- Local Institution - 2110 — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in District of Columbia: - Avenzo Therapeutics Recruiting Site — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in District of Columbia: - Georgetown University Lombardi Cancer Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pemb…
Sponsor: Georgetown University
NCT ID: NCT04865887
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Medstar Washington Hospital Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in District of Columbia: - John Hopkins Kimmer Cancer Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…
Sponsor: Exelixis
NCT ID: NCT06545331
Sites in District of Columbia: - Exelixis Clinical Site #10 — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…
Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in District of Columbia: - Sibley Hospital - Johns Hopkins University — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Recruiting NIH
Background: Researchers want to learn more about head and neck disorders. Understanding these disorders could help them find better treatments. To do this, they are collecting tissue samples for research. Objective: To create a repository …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03429036
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Johns Hopkins Hospital Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help par…
Sponsor: Georgetown University
NCT ID: NCT06980103
Sites in District of Columbia: - Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduc…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05658731
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
The goal of this clinical trial is to test whether an interactive, video-based patient navigation program can improve cervical cancer screening among African American women who are currently overdue for screening. The main questions it aim…
Sponsor: ISA Associates, Inc.
NCT ID: NCT07011836
Sites in District of Columbia: - Family and Medical Counseling Service, Inc. — Washington D.C., District of Columbia